Gene Editing Technologies Market - Global Industry Analysis and Forecast 2017 - 2025


Persistence Market Research

$ 4900

Advancements in genetic engineering facilitated the development of targeted gene nucleases, which opened up huge opportunity for researcher to manipulate any genomic sequence. Targeted nucleases are used to cut the genomic sequence at definite site in order to stimulate mutation, addition or deletion of particular sequence. The first tool used for gene editing was zinc-finger nucleases, which experienced slow adoption due to high cost constraint. Genome editing or gene editing technologies has accelerated research pace in the field of disease modelling and drug discovery, human gene therapy, synthetic biology, neuroscience, agricultural science etc. Despite of potential difficulties in the field of specific nucleases, scientists are constantly taking efforts to enhance their specificity. Gene editing may result into loss of function or gain of function of the. Gene editing technologies are also of vital importance in the horticulture for plant breeding and hybridization and is becoming a hallmark of modern horticulture. Till date over 25,000 human genes are annotated and approximately 3000 mutations are already being linked to the disease phenotype, which makes therapeutic gene editing painless over time. This has enabled new treatment options for many conditions such as vision restoration in blind patients, targeted cancer therapy, identification of specific treats of infectious species, treatment of hemophilia, etc.

The global market for gene editing technologies is expected to be driven by need for strong treatment alternatives for fatal conditions such as cancer, HIV, hemophilia, LSDs etc., increasing funding technological advancements in genome sequencing, increasing funding form government for life science research etc. Apart from this, drop in sequencing cost, completion of human genome project, and ever increasing size of human genome sequencing data for diseased individuals etc. are some of the factors fueling the growth of global gene editing technologies market over the forecast period. Whereas, challenges to delivery of targeted nucleases to specific site and at sufficient amount to achieve efficient target disruption, limited resources and skilled professionals to perform these critical operations, etc. are the factors limiting the growth of global gene editing technologies market.

The global market for gene editing technologies is segmented on basis of technology, application, end user and geography:

  • Segmentation by Technology
    • Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-cas9
    • Transcription Activator-like Effector Nucleases (TALEN)
    • Zinc-finger Nucleases (ZFNs)
    • Homing Endonucleases or Meganucleases
  • Segmentation by Application
    • Cell Line Engineering
    • Animal Genetic Engineering
    • Plant Genetic Engineering
    • Others
  • Segmentation by End User
    • Biotechnology Industry
    • Horticulture Industry
    • Animal Breeding
    • Academic and Research Institutes

Zink finger nucleases (ZFNs) is expected to be the most commonly used gene editing technology as the other technologies are in nascent stage. However, CRISPR segment is expected to grow at highest CAGR due to continuous researches in the application of CRISPR. Moreover, targeting efficiency of CRISPR is more when compared to that with TALENs and ZFNs.

Based on end user, the global gene editing technologies market has been segmented into biotechnology industry, horticulture industry, animal breeding and academic & research institutes. Academic and research institutes are expected to contribute maximum share in the global gene editing technologies market over the f recast period as majority of the therapeutic applications of gene editing are not yet commercialized.

On the basis of regional presence, global gene editing technologies market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global market due to increasing number academic and research institutes. Market in APAC region is expected to witness significant growth rate over the forecast period owing to expansion activities by key market players in the region.  

Some of the players operating in global gene editing technologies market are Thermo Fisher Scientific Inc., RGen Solutions, New England Biolabs Inc., Sigma-Aldrich Co. LLC. (subsidiary of Merck KGaA), GeneCopoeia, Inc., Genscript Biotech Corporation, OriGene Technologies, Inc., Agilent Technologies, Lonza Group and others. 

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.